You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.

TD Cowen downgrades Novo Nordisk on concerns over semaglutide patent loss, pipeline outlook ○

found 2026 › Mar › 10 (Tue) @ 11:34 UTC

a story from CNBC ⚠️ › Top News

Novo Nordisk ■

TD Cowen still sees shares of Novo Nordisk adding 6% from here.